ANDA Median Approval Times Still Rising, But What Does It Mean?

First quarterly report of median US generic drug times shows longer time to approval than previous estimates, but that may not tell stakeholders much.

FDA entrance sign 2016

The US FDA is reporting median and mean ANDA approval times quarterly as part of GDUFA II, but the data may not offer much help for stakeholders tracking agency performance.

The report suggests ANDA approval times continue to slow, despite more than five years working under the generic drug user...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from US FDA

More from Agency Leadership